Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine
- Sponsor
- Theis S. Itenov
- Study ID
- NCT07273071
- Phase
- PHASE4
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Acute Infection
- Sepsis
- Severe Infection
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- N-Acetylcysteine (NAC) Treatment — DRUGIntravenous infusion of N-acetylcysteine (200 mg/kg mixed with normal saline to a final volume of 500 ml) administered over four hours.
Study Details
The primary objective of the IMPACT-NAC trial is to assess the effects of N-acetylcysteine on survival and hospital length of stay in adults admitted to the emergency department with acute infection or sepsis and evidence of liver dysfunction. The main question it aims to answer is: does N-acetylcysteine increase the number of days alive and out of the hospital within the first 14 days after enrolment in the trial? To answer this question, we will conduct a randomized, double-blinded controlled trial of 360 participants. Participants will be randomized to either N-acetylcysteine or placebo (normal saline without active drugs). This will be administered as an infusion during four hours within the first day of hospital admission.
Key Dates
- First listed
- Dec 9, 2025
- Start date
- Jul 31, 2026
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2027
- Completion
- May 31, 2028
Study Design
- Enrollment
- 360 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: N-acetylcysteine
- No Intervention: Placebo (normal saline)
Primary Outcome Measure
Days alive and out of hospital at 14 days post-randomization (DAOH-14) [ Time Frame: Assessed 14 days post-randomization ]
Central Contacts
- Frans Wiberg, MD+4528741294
- Theis S Itenov, MD, PhD
Related Studies
- Alveolar Dead Space as Predictor of Organ Failure in Severe SepsisNot Yet Recruiting · The University of Texas Health Science Center, Houston · Houston, Texas
- Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?Recruiting · Michigan State University · Lansing, Michigan
- Biomarkers in InfectionRecruiting · Beth Israel Deaconess Medical Center · Boston, Massachusetts
- STUDY00015328: Sepsis EndotypesEnrolling By Invitation · Milton S. Hershey Medical Center · Hershey, Pennsylvania